ARUP's Laboratory Test Directory

0050591: GM1 Antibody Panel

Test Mnemonic: GM1 PAN
Methodology: Enzyme-Linked Immunosorbent Assay

Performed: Tue, Fri

Reported: 1-5 days

Specimen Required:  
Collect: One 4 mL SST.

Transport: 1 mL serum, frozen.  (Min: 0.5 mL)  If MAG Ab is ordered on the same patient, submit two 1 mL aliquots, frozen.  Submit specimen in an ARUP Standard Transport Tube.

Pediatric Collection/Transport: 0.25 mL serum, frozen.

Remarks: CRITICAL FROZEN. Separate serum from cells ASAP.

Unacceptable Conditions: Ambient or refrigerated specimens. Plasma and other body fluids. Heat-inactivated, severely lipemic, contaminated, or hemolyzed specimens.

Stability: After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable;  Frozen: 1 year

Reference Interval:
 
Test Number Components Reference Interval
 GM1 Antibody IgG 29 IV or less: Negative
30-50 IV: Weak positive
51-150 IV: Positive
151 IV or greater: Strong positive
 GM1 Antibody, IgM 29 IV or less: Negative
30-50 IV: Weak positive
51-150 IV: Positive
151 IV or greater: Strong positive
 Asialo GM1 Antibody, IgG 29 IV or less: Negative
30-50 IV: Weak positive
51-150 IV: Positive
151 IV or greater: Strong positive
 Asialo GM1 Antibody, IgM 29 IV or less: Negative
30-50 IV: Weak positive
51-150 IV: Positive
151 IV or greater: Strong positive

Interpretive Data:
Elevated antibody levels to ganglioside-monosialic acid (GM1), a glycolipid, have been shown in some instances to be associated with certain neurological disorders such as: lower motor neuron syndrome, amyotrophic lateral sclerosis, multiple sclerosis, other multifocal neuropathies, and systemic lupus erythematosus (SLE) with central nervous system involvement.  Some normal individuals have low levels of GM1 antibodies.  GM2 and GD1a antibodies have been associated with Guillaino-Barrvariants, motor neuropathies and sensory demyelinating neuropathy while FD1b has been associated with sensory neuropathy.  GQ1b has been associated with motor and sensorimotor neuropathies, Miller-Fisher syndrome and Bickerstaff's brainstem encephalitis. The cause of such disorders is not fully understood and, therefore, the significance of elevated antibody levels has not been adequately established.  The test has been designed to be an aid in the monitoring of changes in antibody levels before, during, and after treatment and may be helpful to the clinician in conjunction with other tests and clinical symptoms for the evaluation of  treatment in these patients.

Please refer to Statement D in the Compliance Statements section in the front of the Laboratory Test Directory.



CPT Code(s):
83516 GM1 G; 83516 GM1 M; 83516 Asialo GM1 G; 83516 Asialo GM1 M

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org